Andromeda Surgical accelerates its development by using a commodity robotic arm from KUKA. This strategy allows them to focus resources on their core IP—the AI and software autonomy layer—rather than sinking capital and time into custom hardware development.

Zyda raised funds primarily from urologists and urogynecologists. These clinician-investors already understood the market need, provided crucial industry connections (like finding a clinical trial investigator), and became influential early prescribers, dramatically accelerating market entry and validation.

Augurex's CEO identified a major opportunity by noting that biomarker use in rheumatology was 10-15 years behind oncology. This "technology lag" between medical specialties signals a significant unmet need and a prime area for innovation, allowing proven concepts from one field to revolutionize another.

By releasing new software features weekly based on direct feedback from surgeons in the clinic, Andromeda has compressed the typical multi-year MedTech development cycle into weeks. This rapid, customer-centric improvement loop is shocking to the traditionally slow-moving medical industry.

Experts advise platform technology founders to resist showcasing broad applicability. Instead, they should focus on specific use cases where they can generate compelling evidence, such as for a particular disease or drug modality. This builds credibility and creates a "beachhead" for future expansion.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

For ambitious projects like surgical robotics with long development timelines, relying solely on traditional VC is risky. RoboCath found that bringing in corporate investors provided a long-term strategic vision and reassured other shareholders, which is critical for survival.

The robotic platform's success was driven by a physician-founder's focus on three core needs: being precise and efficient, being user-friendly by working with all existing third-party devices, and being affordable for hospitals.

While remote procedures are a long-term goal, the immediate drivers for robotic adoption in cardiology are more practical. They solve physicians' "awful" working conditions (radiation, physical strain) and enhance interventions with a level of precision that humans cannot achieve.